LFMD vs. SMED, AUNA, AIRS, SHLT, PTWO, TOI, MRM, NVOS, AIH, and OTRK
Should you be buying LifeMD stock or one of its competitors? The main competitors of LifeMD include Sharps Compliance (SMED), Auna (AUNA), AirSculpt Technologies (AIRS), SHL Telemedicine (SHLT), Pono Capital Two (PTWO), Oncology Institute (TOI), MEDIROM Healthcare Technologies (MRM), Novo Integrated Sciences (NVOS), Aesthetic Medical International Holdings Group (AIH), and Ontrak (OTRK).
LifeMD (NASDAQ:LFMD) and Sharps Compliance (NASDAQ:SMED) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, media sentiment, community ranking, risk, institutional ownership, earnings, dividends and analyst recommendations.
Sharps Compliance has lower revenue, but higher earnings than LifeMD. LifeMD is trading at a lower price-to-earnings ratio than Sharps Compliance, indicating that it is currently the more affordable of the two stocks.
Sharps Compliance received 213 more outperform votes than LifeMD when rated by MarketBeat users. However, 71.79% of users gave LifeMD an outperform vote while only 51.72% of users gave Sharps Compliance an outperform vote.
Sharps Compliance has a net margin of 7.88% compared to LifeMD's net margin of -14.75%. Sharps Compliance's return on equity of 5.48% beat LifeMD's return on equity.
In the previous week, LifeMD had 5 more articles in the media than Sharps Compliance. MarketBeat recorded 5 mentions for LifeMD and 0 mentions for Sharps Compliance. LifeMD's average media sentiment score of 0.85 beat Sharps Compliance's score of 0.00 indicating that LifeMD is being referred to more favorably in the media.
LifeMD presently has a consensus target price of $12.50, indicating a potential upside of 65.78%. Given LifeMD's higher possible upside, analysts clearly believe LifeMD is more favorable than Sharps Compliance.
LifeMD has a beta of 1.16, suggesting that its share price is 16% more volatile than the S&P 500. Comparatively, Sharps Compliance has a beta of 1.28, suggesting that its share price is 28% more volatile than the S&P 500.
35.5% of LifeMD shares are owned by institutional investors. Comparatively, 56.1% of Sharps Compliance shares are owned by institutional investors. 18.9% of LifeMD shares are owned by company insiders. Comparatively, 4.8% of Sharps Compliance shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Summary
Sharps Compliance beats LifeMD on 10 of the 17 factors compared between the two stocks.
Get LifeMD News Delivered to You Automatically
Sign up to receive the latest news and ratings for LFMD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LFMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
